Avalo Therapeutics (AVTX) Research & Development (2014 - 2026)
Avalo Therapeutics posted quarterly Research & Development of $14.0 million for Q1 2026, up 53.97% year-on-year from $9.1 million in Q1 2025, and up 5.88% on a QoQ basis from $13.3 million in Q4 2025.
Avalo Therapeutics (AVTX) has 13 years of Research & Development data on file, last reported at $14.0 million in Q1 2026.
- For the quarter ending Q1 2026, Research & Development rose 53.97% year-over-year to $14.0 million; the trailing twelve-month figure through Mar 2026 stood at $55.0 million (up 74.94% YoY), and the FY2025 full-year result was $50.1 million, up 104.95% from the prior year.
- Research & Development for Q1 2026 stood at $14.0 million, up from $13.3 million in the prior quarter.
- Across five years, Research & Development topped out at $14.1 million in Q2 2025 and bottomed at $1.2 million in Q3 2023.
- The 5-year median for Research & Development is $8.2 million (2024), against an average of $7.9 million.
- The widest annual swing landed in 2023, when Research & Development slumped 82.26%; it then soared 663.65% in 2024.
- A 5-year view of Research & Development shows it stood at $6.2 million in 2022, then slumped by 69.75% to $1.9 million in 2023, then surged by 338.3% to $8.2 million in 2024, then soared by 62.13% to $13.3 million in 2025, then rose by 5.88% to $14.0 million in 2026.
- The last three Research & Development figures came in at $14.0 million (Q1 2026), $13.3 million (Q4 2025), and $13.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - | 14.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.05 Mn |
| Dec 31, 2025 | 13.27 Mn |
| Sep 30, 2025 | 13.62 Mn |
| Jun 30, 2025 | 14.07 Mn |
| Mar 31, 2025 | 9.12 Mn |
| Dec 31, 2024 | 8.18 Mn |
| Sep 30, 2024 | 9.54 Mn |
| Jun 30, 2024 | 4.60 Mn |
| Mar 31, 2024 | 2.12 Mn |
| Dec 31, 2023 | 1.87 Mn |
| Sep 30, 2023 | 1.25 Mn |
| Jun 30, 2023 | 4.66 Mn |
| Mar 31, 2023 | 6.01 Mn |
| Dec 31, 2022 | 6.17 Mn |
| Sep 30, 2022 | 7.04 Mn |
| Jun 30, 2022 | 8.51 Mn |
| Mar 31, 2022 | 9.58 Mn |
| Dec 31, 2021 | 11.51 Mn |
| Sep 30, 2021 | 10.55 Mn |
| Jun 30, 2021 | 12.57 Mn |
| Mar 31, 2021 | 25.21 Mn |
| Dec 31, 2020 | 12.64 Mn |
| Sep 30, 2020 | 8.87 Mn |
| Jun 30, 2020 | 5.92 Mn |
| Mar 31, 2020 | 4.77 Mn |
| Dec 31, 2019 | 2.91 Mn |
| Sep 30, 2019 | 1.74 Mn |
| Jun 30, 2019 | 3.71 Mn |
| Mar 31, 2019 | 3.40 Mn |
| Dec 31, 2018 | 2.01 Mn |
| Sep 30, 2018 | 1.05 Mn |
| Jun 30, 2018 | 1.08 Mn |
| Mar 31, 2018 | 1.65 Mn |
| Dec 31, 2017 | 1.96 Mn |
| Sep 30, 2017 | 964,574.00 |
| Jun 30, 2017 | 493,649.00 |
| Mar 31, 2017 | 953,071.00 |
| Dec 31, 2016 | 773,000.00 |
| Sep 30, 2016 | 4.58 Mn |
| Jun 30, 2016 | 2.50 Mn |
| Mar 31, 2016 | 2.29 Mn |
| Dec 31, 2015 | 1.75 Mn |
| Sep 30, 2015 | 1.24 Mn |
| Jun 30, 2015 | 1.88 Mn |
| Mar 31, 2015 | 1.72 Mn |
| Dec 31, 2014 | 2.26 Mn |
| Sep 30, 2014 | 4.37 Mn |